Current global surveillance from the World Health Organization and CDC shows no novel pathogen has triggered sustained human-to-human transmission capable of meeting pandemic criteria in 2026. Respiratory virus activity, including COVID-19 Omicron sublineages such as Cicada BA.3.2, remains at low or declining levels with reproduction numbers near or below one, while localized outbreaks like the recent hantavirus cases linked to cruise travel and ongoing mpox circulation carry official low-risk assessments to the general public. Monitoring of zoonotic threats including H5N1 influenza and Marburg virus reveals no evidence of efficient airborne spread or exponential growth, consistent with historical patterns where true pandemics emerge infrequently. Traders appear to weigh these stable epidemiological indicators heavily against the inherent uncertainty of future spillovers, with upcoming seasonal influenza updates and variant tracking likely to provide further clarity.